Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Abstract A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-base...

Full description

Bibliographic Details
Main Authors: Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu, Xianjun Yu
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Journal of Hematology & Oncology
Subjects:
Pancreatic ductal adenocarcinoma
Novel regimens
Biomarkers
Combination therapies
Online Access:http://link.springer.com/article/10.1186/s13045-017-0551-7

Internet

http://link.springer.com/article/10.1186/s13045-017-0551-7

Similar Items